Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation ...

The global populating is aging, and approximately 29% of people with diabetes worldwide are aged 65 years and older, ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused ...

Novo Nordisk will continue pursuing legal action to protect patients from the risks posed by unapproved knockoff drugs and foreign illicit active pharmaceutical ingredients (API). The prevalence ...

A company that could have learned that lesson earlier is Novo Nordisk, the drugmaker that turned an obscure hormone into a weight-loss blockbuster. Its shares have more than halved since last ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Outside of pipeline issues, Novo Nordisk and the rest of the pharmaceutical industry are grappling with the Trump administration's ambitions to lower drug prices and bring manufacturing to the U.S ...